In the last trading session, 2.63 million Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares changed hands as the company’s beta touched 1.06. With the company’s per share price at $47.00 changed hands at $2.56 or 5.76% during last session, the market valuation stood at $5.39B. APLS’s last price was a discount, traded about -101.6% off its 52-week high of $94.75. The share price had its 52-week low at $19.83, which suggests the last value was 57.81% up since then. When we look at Apellis Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 1.95 million shares, with the 3-month average coming to 4.83 million.
Analysts gave the Apellis Pharmaceuticals Inc. (APLS) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 15 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 4 recommended APLS as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight. Apellis Pharmaceuticals Inc.’s EPS for the current quarter is expected to be -$1.12.
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) trade information
Instantly APLS was in green as seen at the end of in last trading. With action 13.23%, the performance over the past five days has been green. The jump to weekly highs of 47.17 on Monday, 09/18/23 added 5.76% to the stock’s daily price. The company’s shares are showing year-to-date downside of -9.11%, with the 5-day performance at 13.23% in the green. However, in the 30-day time frame, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is 52.10% up. Looking at the short shares, we see there were 12.31 million shares sold at short interest cover period of 2.06 days.
The consensus price target for the stock as assigned by Wall Street analysts is $67.64, meaning bulls need an upside of 30.51% from its current market value. According to analyst projections, APLS’s forecast low is $29.00 with $95.00 as the target high. To hit the forecast high, the stock’s price needs a -102.13% plunge from its current level, while the stock would need to tank 38.3% for it to hit the projected low.
Apellis Pharmaceuticals Inc. (APLS) estimates and forecasts
Data shows that the Apellis Pharmaceuticals Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -25.42% over the past 6 months, a 20.49% in annual growth rate that is considerably higher than the industry average of 11.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Apellis Pharmaceuticals Inc. will rise 36.00%, while the growth in revenue is estimated to hit 32.00% for the next quarter. Year-over-year growth is forecast to reach 311.80% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of $80.97 million. 12 analysts are of the opinion that Apellis Pharmaceuticals Inc.’s revenue for the quarter ending Dec 2023 will be $90.83 million. The company’s revenue for the corresponding quarters a year ago was $22.06 million and $22.66 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 267.10%. The estimates for the next quarter sales put growth at 300.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -42.80%. The 2023 estimates are for Apellis Pharmaceuticals Inc. earnings to increase by 30.50%, but the outlook for the next 5-year period is at 33.30% per year.
Apellis Pharmaceuticals Inc. is expected to release its next quarterly earnings report between November 06 and November 10.
Apellis Pharmaceuticals Inc. (NASDAQ:APLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.63% of Apellis Pharmaceuticals Inc. shares while 96.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.04%. There are 96.76% institutions holding the Apellis Pharmaceuticals Inc. stock share, with Avoro Capital Advisors LLC the top institutional holder. As of Jun 29, 2023, the company held 9.44% of the shares, roughly 11.11 million APLS shares worth $1.01 billion.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 7.98% or 9.4 million shares worth $856.46 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Apr 29, 2023 were Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund. With 4.1 million shares estimated at $342.15 million under it, the former controlled 3.48% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.64% of the shares, roughly 3.11 million shares worth around $283.01 million.